๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders

โœ Scribed by Kerry J. Ressler; Charles B. Nemeroff


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
168 KB
Volume
12
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

โœฆ Synopsis


There is abundant evidence for abnormalities of the norepinephrine (NE) and serotonin (5HT) neurotransmitter systems in depression and anxiety disorders. The majority of evidence supports underactivation of serotonergic function and complex dysregulation of noradrenergic function, most consistent with overactivation of this system. Treatment for these disorders requires perturbation of these systems. Reproducible increases in serotonergic function and decreases in noradrenergic function accompany treatment with antidepressants, and these alterations may be necessary for antidepressant efficacy. Dysregulation of these systems clearly mediates many symptoms of depression and anxiety. The underlying causes of these disorders, however, are less likely to be found within the NE and 5HT systems, per se. Rather their dysfunction is likely due to their role in modulating, and being modulated by, other neurobiologic systems that together mediate the symptoms of affective illness. Clarification of noradrenergic and serotonergic modulation of various brain regions may yield a greater understanding of specific symptomatology, as well as the underlying circuitry involved in euthymic and abnormal mood and anxiety states. Disrupted cortical regulation may mediate impaired concentration and memory, together with uncontrollable worry. Hypothalamic abnormalities likely contribute to altered appetite, libido, and autonomic symptoms. Thalamic and brainstem dysregulation contributes to altered sleep and arousal states. Finally, abnormal modulation of cortical-hippocampal-amygdala pathways may contribute to chronically hypersensitive stress and fear responses, possibly mediating features of anxiety, anhedonia, aggression, and affective dyscontrol. The continued appreciation of the neural circuitry mediating affective states and their modulation by neurotransmitter systems should further the understanding of the pathophysiology of affective and anxiety disorders.


๐Ÿ“œ SIMILAR VOLUMES


Uncoupling of serotonergic and noradrene
โœ Thomas D. Geracioti Jr.; Peter T. Loosen; Nosa N. Ekhator; Dennis Schmidt; Bryon ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 119 KB ๐Ÿ‘ 1 views

## We used the technique of continuous cerebrospinal fluid (CSF) sampling to test the following hypotheses regarding CNS monoaminergic systems in depression: (1) absolute concentrations of the informational substances tryptophan and 5hydroxyindoleacetic acid (5-HIAA) are altered in the CNS of depres

An evaluation of the role of the noradre
โœ Anna M. Redmond; Brian E. Leonard ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 275 KB ๐Ÿ‘ 1 views

With increased understanding of the neurobiology of depression, the role of the noradrenergic system is achieving greater signiยฎcance. Unfortunately, the exact role of noradrenaline in depressive disorders is dicult to determine due to contradictory and inconsistent results from metabolite (MHPG) an

Assessment of locus of control in patien
โœ Barbara L. Kennedy; Gregory V. Lynch; John J. Schwab ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 73 KB ๐Ÿ‘ 1 views

We studied Levenson's Internal (I), Powerful Others (P), and Chance (C) locus of control scales in 193 patients with six DSM-III-R diagnoses: Major Depression (MD), Panic Disorder (PD), Generalized Anxiety Disorder (GAD), Social Phobia (SP), Obsessive Compulsive Disorder (OCD), and Mixed Anxiety Dep

Controlled Comparison of Tianeptine, Alp
โœ MARC ANSSEAU; MICHEL BATAILLE; GUY BRIOLE; ANDRร‰ DE NAYER; PIERRE ANDRร‰ FAUCHรˆRE ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 439 KB ๐Ÿ‘ 1 views

A multicentre study compared tianeptine (37.5 mg/day), an original psychotropic compound characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, mianserin (60 mgkday) and a reference anxiolytic, alprazolam (1.5 mglday), in the treatment of 152 patients fulfil